The United States has gotten comfortable in its role as the undisputed global leader in biomedical research and manufacturing. Over the past 30 years, many European multinational firms shifted R&D to the U.S. to take advantage of its matchless ecosystem for innovation. But today, other countries realize the value of attracting R&D in the life sciences, and the private-sector production activities associated with it, for creating high-value-added jobs. Many Asian and European nations are pursuing strategies to wrestle biomedical innovation infrastructure away from the United States. What policy moves should the U.S. implement to keep its leadership in this field intact?
Vice President, Advancing Innovation, Kauffman Foundation
Executive Director, Economic Research, Milken Institute
Chief Technology Officer, CT & AW Engineering, General Electric
Deputy Chairman, Biomedical Research Council, Agency for Science, Technology, and Research (A*STAR)
Former Governor, State of Utah; former Secretary of Health and Human Services